Independent pharmacies adapt to specialty drugs, biosimilars, cold-chain, and REMS demands.
News|Articles|February 26, 2008
GAO: Part D plan sponsors can improve their drug coverage performance
A new Government Accountability Office report concludes that some Medicare Part D drug plan sponsors are dragging their feet when notifying beneficiaries of their drug coverage decisions.
Advertisement
Advertisement
Related to this article
During American Pharmacists Month, pharmacy teams reflect on their roles and explore ways to enhance patient care.
Lara Zakaria, PharmD, MS, CNS, FMCP, discusses her perspectives regarding the emergence of wearable technology among community pharmacy patients.
Diabetes medication experts focus on practical access and pharmacist counseling considerations for adults on obesity medication.
The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.
Melissa McGivney, PharmD, FAPhA, FCCP, helps celebrate American Pharmacists Month and the innovation driving the profession forward amongst US communities.
Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.
The novel tool can be used to inform vaccine policy, monitor impact, and essentially strengthen overall surveillance.
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacists Improve Access, Safe Use of Obesity Medications
2
Is Your Independent Pharmacy Ready for New Therapies and Innovations?
3
FDA Approves New Drug for HSV Lesions in Adults
4
Wearable Tech as a Revenue, Clinical Service Opportunity for Pharmacists | NCPA 2026
5